Big Pharma's face moderate ESG risk exposure but limited materiality to valuation

2 February 2023
marketreportbig

In Morningstar’s recent ESG Industry Landscape ReportBiopharma, its analysts found that large drug manufacturers face moderate environmental, social and governance (ESG) risk exposure but have limited materiality to valuation. More specifically, access to basic services, product governance, and business ethics are the three most material ESG risks to pharma and biotech companies.

Access to basic services is potentially one of the most prominent ESG risks to biopharma firms, according to Morningstar’s report, where drug pricing complexity creates issues of affordability among end users. Very few people know the exact net prices any buyer pays after rebates and discounts. Determining the fairness of that price is even more complex.

Product governance is also a critical consideration of ESG risk given the very nature of drugs themselves. However, although legal costs are prevalent, the materiality of this ESG risk remains low given firms’ much larger profits.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical